Sponsor & Developer Portfolio
Singapore General Hospital
Clinical development pipeline, platform architecture, and registered trial tracking for Singapore General Hospital vaccine candidates.
1
Candidates
1
Target Diseases
1
Linked Studies
Development Phase Distribution
Phase 2 Clinical Trial: 1
Platform Technologies
Biological (unspecified platform): 1
Target Pathogens & Indications
Immune System Responses and Trained Immunity After AS01 Administration
Vaccine Pipeline Candidates (1)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Phase 2 Clinical Trial
ctgov-as01-adjuvant-0-5-ml-intramuscular-singapore-general-hospital
YF17D (Stamaril, Sanofi-Pasteur)
Target: Immune System Responses and Trained Immunity After AS01 Administration
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2029-02-28 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.